Newborn Calf Serum Market
From calves that are 3 to 10 days old, Newborn Calf Serum (NBCS) is created. Fetal bovine serum is more expensive and of lower quality than NBCS. Neonatal calf serum (NBCS), which is more cheap and widely accessible than foetal bovine serum, is favoured as a basal growth medium. Newborn calf serum is frequently employed when a cell line is difficult and cell attachment is a key concern during cell culture. Additional benefits of neonatal calf serum include- When normal cell development and maintenance are the goal, NBCS performance is good. NBCS is abundant in antibodies needed for immune system development. High levels of protein and immunoglobin are seen in NBCS. The application of NBCS increases the viability of cryopreserved mouse spermatogonial stem cells.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/5331
Impact
Due to an increase in research and development activities pertaining to vaccine manufacture, the COVID-19 pandemic is anticipated to propel the growth of the worldwide newborn calf serum market. For instance, a biotechnology company called Bharat Biotech undertook research in 2020 to develop the COVID-19 vaccine, using newborn calf serum as one of the essential ingredients for raising vero cell lines. These cell lines were utilised for the production of vaccinations. To evaluate the effectiveness, composition, etc. of vaccination agents, cell culture is used.
After COVID-19, an increase in the number of clinical trials to find novel drugs is anticipated to fuel the growth of the worldwide newborn calf serum market.
For instance, a review article on clinical trials conducted following COVID-19 was published in the Frontiers magazine in 2020. The reported data show a significant increase in clinical trials for the creation of new medicines. Serum is one of the primary ingredients of the growing medium used to generate cell lines, which are used to evaluate potential medications prior to clinical trials. Clinical experiments are using cell lines more frequently, which is projected to lead to a rise in the usage of new-born calf serum.
The market for neonatal calf serum is anticipated to reach US$ 222.2 million in 2022 and grow at a 6.8% CAGR during the projected period (2022-2030).
The manufacture of newborn calf serum has attracted the attention of pharmaceutical corporations. Over the course of the forecast period, this is anticipated to fuel the expansion of the worldwide newborn calf serum market.
Players in the market are investing in manufacturing facilities to enhance their production capacity, which is anticipated to fuel the expansion of the newborn calf serum market globally. For instance, with a US$1 million investment, Indian Immunologicals Limited, a producer of animal and human vaccines, began operations at its brand-new manufacturing facility in New Zealand in January 2018. One of the most important products produced by this new production facility is newborn calf serum. Due to its desire to have control over the situation, Indian Immunological Limited invested in this.
The global newborn calf serum market is anticipated to rise over the forecast period as a result of key players extending their cell therapy services.
An essential component of cell culture is newborn calf serum. Market participants are making significant investments in cell culture research. The use of newborn calf serum is anticipated to increase in the future as a result of companies expanding their services to include cell treatment, which will accelerate the growth of the worldwide newborn calf serum market. For instance, in June 2022, NorthX Biologics, a biologics company, expanded its services for cell therapy and established Good Manufacturing Practice (GMP)-manufacturing labs at Matfors facility and Karolinska University Hospital campus with the assistance of Alder Therapeutics, a pharmaceutical company. Due to the rising demand from patients and the expanding market for cell therapies, NorthX is expanding.
Market Restraints
Newborn calf serum use is being restricted by animal ethical bodies, which can have a detrimental effect on the market for newborn calf serum globally. People for the Ethical Treatment of Animals (PETA) India asked the drug controller in 2021 to substitute animal-free media for newborn calf serum in the manufacture of vaccinations. Animals under three months of age and pregnant animals cannot be killed, as per the Prevention of Cruelty to Animals Rules, 2001. Because newborn calves have less than 20 days to create newborn calf serum, PETA India warned against its use. The adoption of animal ethics committee regulations and laws on a global scale could slow the growth of the newborn calf serum market. Fetal bovine serum has more growth factors than newborn calf serum. This could decrease consumer interest in using newborn calf serum for cell culture, which could negatively affect the market for newborn calf serum globally.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5331
Market Regional Analysis
The neonatal calf serum market is divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa based on region.
Due to a growth in vaccine production, the North American newborn calf serum market is anticipated to keep a leading position during the forecast period. For instance, the pharmaceutical giant Merck & Company Incorporation raised its global vaccination supply to 190 million doses in 2019. In addition, Merck increased its manufacturing capacity to assist Johnson & Johnson in the production of Covid-19 vaccine. Johnson & Johnson’s vaccine will be produced, formulated, and filled into vials at Merck’s facilities in the United States.
Due to increased cooperation with other market participants, it was anticipated that the newborn calf serum market in Europe would expand significantly over the course of the forecast year. For instance, on June 25, 2022, the biotechnology business BioNTech and the pharmaceutical and biotechnology company Pfizer Inc. partnered to test the safety, tolerability, and immunogenicity of two COVID-19 vaccine candidates that had been modified for Omicron and reported a favourable outcome. They also intend to consult with scientific and medical authorities about these findings, which will allow them to provide an Omicron-adapted booster to the market as soon as possible.
Support from the French government in the form of an interest-free loan to create independent biotech businesses is anticipated to propel the market for newborn calf serum to expansion. For instance, TreeFrog Therapeutics, a biotechnology business established in France in 2018, acquired a US$ 66.7654 M Series B investment in 2021, allowing the business to begin expanding its staff and production facilities for cell therapies internationally. The money will also be used to extend and bring a variety of cell therapies closer to the clinic, as well as to create biomimetic C-StemTM technology for clinical-grade production.
A growing investment in the life science industry is likely to cause the newborn calf serum market in Asia Pacific to develop at the quickest rate during the forecast period. For instance, the international investment company Actis stated on June 28, 2022, that it would invest over US$ 700 million to build life science real estate in India. The investment is intended to create and expand assets under its platform with the goal of offering real estate to customers in India’s life sciences and associated industries. Through which the market for calf serum is anticipated to grow.
Competitive Landscape
Zhejiang Tianhang Biotechnology, Thermo Fisher Scientific Inc., GE Healthcare, Serana, Sartorius AG, Rockey Mountain Biologicals, Merck KGaA, Atlanta Biologicals, Inc., Corning Inc., PAN-Biotech GmbH, Atlas Biologicals, Inc., Capricorn Scientific, TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., and Novus Biologicals, LLC, and are significant market participants.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/5331
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Newborn Calf Serum Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Newborn Calf Serum Industry Impact
Chapter 2 Global Newborn Calf Serum Competition by Types, Applications, and Top Regions and Countries
2.1 Global Newborn Calf Serum (Volume and Value) by Type
2.3 Global Newborn Calf Serum (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Newborn Calf Serum Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Newborn Calf Serum Market Analysis
Chapter 6 East Asia Newborn Calf Serum Market Analysis
Chapter 7 Europe Newborn Calf Serum Market Analysis
Chapter 8 South Asia Newborn Calf Serum Market Analysis
Chapter 9 Southeast Asia Newborn Calf Serum Market Analysis
Chapter 10 Middle East Newborn Calf Serum Market Analysis
Chapter 11 Africa Newborn Calf Serum Market Analysis
Chapter 12 Oceania Newborn Calf Serum Market Analysis
Chapter 13 South America Newborn Calf Serum Market Analysis
Chapter 14 Company Profiles and Key Figures in Newborn Calf Serum Business
Chapter 15 Global Newborn Calf Serum Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com